Example scenarios for Class II and Class III Devices
Class II Example
Virtual simulations for orthopedic implants can predict mechanical fatigue, wear, and stress distribution—ensuring device longevity and reliability before clinical deployment.
Class III Example
Cardiovascular devices (e.g., heart valves or stents) can be simulated to evaluate interaction with blood flow dynamics. This helps anticipate complications such as thrombosis or embolism—critical for pre-trial safety assurance.
How to successfully integrate in-silico testing into MDR compliance
To make in-silico testing count as valid evidence under MDR, manufacturers should:
- Clearly document and validate the computational models used
- Integrate results with traditional clinical and bench data in the CER
- Collaborate with notified bodies to clarify expectations and ensure alignment of computational evidence with regulatory requirements with regards to the appraisal of these in-silico trials
Regulators want traceability, transparency, and technical justification—especially for high-risk or novel devices.
Conclusion: a strategic move toward MDR compliance
In-silico testing under MDR is not just an option—it’s a smart strategic choice. It enables design decisions, faster iterations, earlier risk detection, and stronger technical files. As regulatory expectations evolve, embracing in silico testing puts you ahead of the compliance curve—while also improving patient safety and reducing reliance on traditional testing methods.
关于作者
Navigate Regulatory Complexity with Confidence
Navigate complex regulatory landscapes with expert guidance across pharmaceuticals, medical devices, and IVD.
Read more订阅生命科学领域的最新动态
专家观点直达您的收件箱——选择您的兴趣。
绝无垃圾邮件。随时取消订阅。
